Bedrijfsoverzicht
MetaVia Inc. is a clinical-stage biotechnology enterprise dedicated to the development of novel pharmaceutical interventions designed to treat cardiometabolic diseases. The company operates within the healthcare sector, specifically the biotechnology industry, which focuses on the research and creation of biological drugs and medical technologies. As of the latest data, the entity maintains a market capitalization of $7.18M and employs a workforce of 8 individuals. These valuation and headcount figures indicate that MetaVia is a micro-cap entity with a very small operational footprint, suggesting it is in an early stage of commercialization where capital efficiency is critical for survival and development progress.
Financiële gezondheid
The company reports a Net Income (TTM) of $-12,973,000 and an EBITDA of $-13,689,000, while annual revenue data is not available for calculation. The substantial gap between the reported net income and EBITDA figures reveals that the company's cost structure is heavily influenced by significant non-operating expenses or interest costs, given that the difference between the two metrics is approximately $716,000 in negative cash impact. Free Cash Flow stands at $-11,278,500, which indicates that the company is currently burning cash to fund its research and development activities rather than generating positive cash flow from operations. The Gross Margin, Operating Margin, and Profit Margin are all recorded at 0.0%, indicating that the company has not yet achieved profitability and that revenue, if any, has not covered the direct costs of goods sold or operating expenses. On the balance sheet, the company holds $10.31M in cash against a debt obligation of $210,000, resulting in a Debt to Equity ratio of 3.94, which suggests a highly leveraged position relative to equity, although the absolute debt amount is small compared to cash reserves. The Current Ratio is 1.93, which indicates that the company possesses sufficient current assets to cover its short-term liabilities with nearly double the liquidity required. Return on Equity is -195.6% and Return on Assets is -62.6%, metrics that reveal that management is currently destroying shareholder value and utilizing assets to generate significant losses rather than returns, a common characteristic for clinical-stage biotechs prior to product approval.
Waarderingsbeoordeling
Trailing P/E and Forward P/E ratios are both listed as N/A, implying that the lack of positive earnings makes traditional earnings-based valuation multiples impossible to calculate, while also suggesting that the market does not currently assign a value based on expected earnings growth. The Price to Book ratio is 0.61, which indicates that the market values the company at a discount to its book value, reflecting the high risk associated with its unproven pipeline and lack of revenue. Price to Sales and EV/EBITDA are also not applicable or effectively zero in a traditional sense due to negative earnings and lack of sales data, suggesting that valuation relies heavily on asset backing rather than income generation or sales multiples. The stock has a 52-Week High of $23.10 and a 52-Week Low of $1.17, providing a massive trading range where the current price sits significantly below the high, highlighting the extreme volatility experienced over the past year. The Beta value is 0.34, which means the stock exhibits low volatility relative to the broader market, moving less than half as much as the market index in a given period.
Growth & Income
Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, meaning there is no historical data available to determine if earnings are growing faster or slower than revenue, nor can a growth trajectory be established. The company does not pay a dividend, as evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, which means the company reinvests all available resources, including its cash reserves, into research and development rather than distributing income to shareholders. The overall growth and income profile is characterized by a complete absence of current profitability and dividend distribution, relying entirely on the potential future success of its Phase 2a clinical candidate DA-1241.